About Us
SERENGEN has been established in June 2019 with a novel DNA-encoded library technology, which was developed at the TU Dortmund University, Germany. The platform represents a step-change in the synthesis of DNA-encoded libraries. For the first time, a broad range of modern organic synthesis methods can be applied in the presence of DNA to construct drug-like scaffolds in a combinatorial approach. Hence, we will deliver truly drug-like hits that are amenable to modern medicinal chemistry accelerating chemical lead generation and optimization.
SERENGEN designs DNA-encoded libraries according to customer's needs. A chemistry validation phase consisting of the three stages: chemistry development, reaction optimization and reaction scoping is followed by the production of the customized DEL. Several exclusivity options are available.
SERENGEN screens DELs against an immobilized protein target. Such DELs can be selected from our DEL collection or can be provided by the client. Hits are identified through their DNA tag after PCR amplification, DNA sequencing and enrichment calculation. Following on- and off-DNA single molecule syntheses and screening, the chemical structure of a pre-agreed number of hits is disclosed. Several exclusivity options are available.